Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
Teladoc Health (NYSE: TDOC) sank 74% last year -- and for one particular reason. The telemedicine giant reported two billion-dollar noncash goodwill impairment charges. Both were linked to the acquisition of chronic-care specialist Livongo.
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.